No. |
薬物名(臨床試験情報から抽出) |
DrugBank |
KEGG DRUG * |
KEGG GENES * |
KEGG PATHWAY |
指定難病告示番号 * |
1 |
13 valent conjugated pneumococcal vaccine |
- |
- |
- |
- |
1件: 265 |
2 |
150 mg gsk1265744b |
- |
- |
- |
- |
1件: 265 |
3 |
300mg gemcabene |
Gemcabene |
- |
- |
- |
1件: 265 |
4 |
600mg gemcabene |
Gemcabene |
- |
- |
- |
1件: 265 |
5 |
[n-trans-3-hexenoyl] human growth hormone releasing factor (1-44) acetate |
Acetate |
- |
- |
- |
1件: 265 |
6 |
Abacavir |
Abacavir |
D00891, D07057 |
- |
- |
3件: 135, 265, 325 |
7 |
Abacavir 300mg twice daily |
Abacavir |
D00891, D07057 |
- |
- |
1件: 265 |
8 |
Abacavir sulfate |
Abacavir |
D00891, D07057 |
- |
- |
1件: 265 |
9 |
Abacavir sulfate, lamivudine and zidovudine |
Lamivudine, Zidovudine |
D00353, D00413 |
- |
- |
1件: 265 |
10 |
Acetate |
Acetate |
- |
- |
- |
40件: 1, 2, 6, 10, 13, 35, 40, 46, 49, 51, 60, 64, 70, 71, 73, 75, 76, 78, 81, 83, 85, 86, 88, 90, 96, 97, 113, 145, 156, 162, 171, 206, 222, 224, 225, 235, 265, 288, 298, 299 |
11 |
Acetyl- l- carnitine |
Levocarnitine |
D02030, D02176, D04713 |
- |
- |
1件: 265 |
12 |
Acetylcarnitine |
Acetylcarnitine |
- |
- |
- |
2件: 2, 265 |
13 |
Acipimox |
Acipimox |
D07190 |
- |
- |
2件: 78, 265 |
14 |
Akcea-angptl3-lrx |
- |
- |
- |
- |
2件: 79, 265 |
15 |
Amprenavir |
Amprenavir |
D00894 |
- |
- |
1件: 265 |
16 |
Aramchol |
Aramchol |
- |
- |
- |
1件: 265 |
17 |
Atazanavir |
Atazanavir |
D01276, D07471 |
- |
- |
1件: 265 |
18 |
Atazanavir (atv) + ritonavir (rtv), continuation of backbone 2 nucleoside reverse transcriptase inhibitor (nrtis) |
Atazanavir |
D01276, D07471 |
- |
- |
1件: 265 |
19 |
Atazanavir (reyataz) |
Atazanavir |
D01276, D07471 |
- |
- |
1件: 265 |
20 |
Atazanavir/ritonavir |
Atazanavir |
D01276, D07471 |
- |
- |
1件: 265 |
21 |
Atorvastatin |
Atorvastatin |
D00258, D00887, D07474 |
1件: HMGCR |
4件: AMPK signaling pathway, Bile secretion, Metabolic pathways, Terpenoid backbone biosynthesis |
17件: 13, 46, 49, 51, 58, 63, 79, 84, 88, 93, 96, 160, 222, 225, 265, 271, 299 |
22 |
Atorvastatin calcium |
Atorvastatin |
D00258, D00887, D07474 |
1件: HMGCR |
4件: AMPK signaling pathway, Bile secretion, Metabolic pathways, Terpenoid backbone biosynthesis |
1件: 265 |
23 |
Avandia administration for 6-12 weeks |
- |
- |
- |
- |
1件: 265 |
24 |
Azt/3tc |
- |
- |
- |
- |
1件: 265 |
25 |
Baricitinib |
Baricitinib |
D10308 |
2件: JAK1, JAK2 |
32件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, Chemokine signaling pathway, Cholinergic synapse, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Growth hormone synthesis, secretion and action, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Measles, NOD-like receptor signaling pathway, Necroptosis, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Prolactin signaling pathway, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis |
8件: 41, 46, 49, 50, 93, 107, 265, 325 |
26 |
Bms-232632 |
Atazanavir |
D01276, D07471 |
- |
- |
1件: 265 |
27 |
Calcium |
Calcium |
- |
- |
- |
24件: 6, 13, 19, 46, 49, 51, 65, 68, 75, 79, 84, 93, 94, 95, 96, 97, 214, 215, 222, 224, 235, 265, 298, 299 |
28 |
Carnitine |
Levocarnitine |
D02030, D02176, D04713 |
- |
- |
8件: 5, 13, 58, 96, 97, 265, 298, 316 |
29 |
Cd-4 guided therapy interruption |
- |
- |
- |
- |
1件: 265 |
30 |
Cholic acid |
Cholic acid |
D10699 |
1件: NR1H4 |
1件: Bile secretion |
4件: 20, 234, 265, 310 |
31 |
Cofactor supplementation (thiamine, riboflavin, l-carnitine) |
Riboflavin |
D00050, D01622, D01913 |
- |
- |
1件: 265 |
32 |
Combivir |
Zidovudine |
D00413 |
- |
- |
1件: 265 |
33 |
Combivir (zidovudine [azt] / lamivudine [3tc]) |
Lamivudine, Zidovudine |
D00353, D00413 |
- |
- |
1件: 265 |
34 |
Continuation of current haart (boosted protease inhibitor [pi] combination + 2 nrtis) |
- |
- |
- |
- |
1件: 265 |
35 |
Cyclophosphamide |
Cyclophosphamide |
D00287, D07760 |
- |
- |
43件: 13, 14, 16, 19, 20, 26, 28, 35, 36, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 52, 56, 60, 61, 62, 65, 66, 84, 85, 93, 96, 162, 164, 172, 222, 224, 265, 274, 283, 284, 285, 288, 326, 331 |
36 |
Didanosine |
Didanosine |
D00296 |
- |
- |
2件: 25, 265 |
37 |
Different haart regimens |
- |
- |
- |
- |
1件: 265 |
38 |
Diosmin |
Diosmin |
D07858 |
- |
- |
1件: 265 |
39 |
Diosminex, 500 mg, tabletki powlekane |
- |
- |
- |
- |
1件: 265 |
40 |
Efavirenz |
Efavirenz |
D00896 |
- |
- |
1件: 265 |
41 |
Efavirenz (efv) |
Efavirenz |
D00896 |
- |
- |
1件: 265 |
42 |
Emtricitabine |
Emtricitabine |
D01199 |
- |
- |
4件: 25, 93, 265, 325 |
43 |
Emtricitabine/tenofovir |
Emtricitabine |
D01199 |
- |
- |
1件: 265 |
44 |
Enfuvirtide |
Enfuvirtide |
D02499 |
- |
- |
2件: 25, 265 |
45 |
Enfuvirtide (t20) |
Enfuvirtide |
D02499 |
- |
- |
1件: 265 |
46 |
Fenofibrate |
Fenofibrate |
D00565 |
1件: PPARA |
7件: Adipocytokine signaling pathway, Glucagon signaling pathway, Hepatitis C, Insulin resistance, Non-alcoholic fatty liver disease (NAFLD), PPAR signaling pathway, cAMP signaling pathway |
5件: 8, 79, 93, 94, 265 |
47 |
Gemcabene |
Gemcabene |
- |
- |
- |
2件: 79, 265 |
48 |
Genotropin (human recombinant growth hormone) |
Somatotropin |
D02691 |
1件: GHR |
5件: Cytokine-cytokine receptor interaction, Growth hormone synthesis, secretion and action, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway |
1件: 265 |
49 |
Glycerine |
Glycerin |
D00028 |
- |
- |
1件: 265 |
50 |
Growth hormone |
Somatotropin |
D02691 |
1件: GHR |
5件: Cytokine-cytokine receptor interaction, Growth hormone synthesis, secretion and action, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway |
11件: 2, 13, 19, 46, 78, 96, 191, 193, 195, 265, 299 |
51 |
Growth hormone releasing hormone |
Somatotropin |
D02691 |
1件: GHR |
5件: Cytokine-cytokine receptor interaction, Growth hormone synthesis, secretion and action, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway |
1件: 265 |
52 |
Gsk1265744b (sodium salt) containing 14c-gsk1265744b |
- |
- |
- |
- |
1件: 265 |
53 |
Hu leptin (a-100) |
Leptin |
- |
- |
- |
1件: 265 |
54 |
Human growth hormone |
Somatotropin |
D02691 |
1件: GHR |
5件: Cytokine-cytokine receptor interaction, Growth hormone synthesis, secretion and action, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway |
3件: 78, 193, 265 |
55 |
Human recombinant leptin (metreleptin) |
Metreleptin |
D05014 |
1件: LEPR |
6件: AMPK signaling pathway, Adipocytokine signaling pathway, Cytokine-cytokine receptor interaction, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, Non-alcoholic fatty liver disease (NAFLD) |
1件: 265 |
56 |
Indinavir |
Indinavir |
D00897, D02861, D03833 |
- |
- |
1件: 265 |
57 |
Isis 304801 |
Volanesorsen |
D11648 |
1件: APOC3 |
2件: Cholesterol metabolism, PPAR signaling pathway |
1件: 265 |
58 |
Kaletra (lopinavir [lpvr]) |
Lopinavir |
D01425 |
- |
- |
1件: 265 |
59 |
L-carnitine |
Levocarnitine |
D02030, D02176, D04713 |
- |
- |
6件: 13, 96, 97, 265, 298, 316 |
60 |
L-lactic acid |
Lactic acid |
D00111 |
- |
- |
1件: 265 |
61 |
Lactic acid |
Lactic acid |
D00111 |
- |
- |
2件: 265, 299 |
62 |
Lamivudine |
Lamivudine |
D00353 |
- |
- |
6件: 26, 42, 46, 135, 265, 325 |
63 |
Lamivudine/zidovudine |
Lamivudine, Zidovudine |
D00353, D00413 |
- |
- |
1件: 265 |
64 |
Leptin |
Leptin |
- |
- |
- |
2件: 6, 265 |
65 |
Lopinavir |
Lopinavir |
D01425 |
- |
- |
2件: 130, 265 |
66 |
Lopinavir/ritonavir |
Lopinavir, Ritonavir |
D00427, D01425 |
- |
- |
1件: 265 |
67 |
Lopinavir/ritonavir + nevirapine |
Nevirapine |
D00435 |
- |
- |
1件: 265 |
68 |
Lopinavir/ritonavir + zidovudine + lamivudine |
Lamivudine, Zidovudine |
D00353, D00413 |
- |
- |
1件: 265 |
69 |
Mecasermin |
Mecasermin |
D03297, D04870 |
2件: GHR, IGF1R |
33件: AMPK signaling pathway, Adherens junction, Autophagy - animal, Breast cancer, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, Endocytosis, Focal adhesion, FoxO signaling pathway, Glioma, Growth hormone synthesis, secretion and action, HIF-1 signaling pathway, Hepatocellular carcinoma, JAK-STAT signaling pathway, Long-term depression, Longevity regulating pathway, Longevity regulating pathway - multiple species, MAPK signaling pathway, Melanoma, Neuroactive ligand-receptor interaction, Oocyte meiosis, Ovarian steroidogenesis, PI3K-Akt signaling pathway, Pathways in cancer, Progesterone-mediated oocyte maturation, Prostate cancer, Proteoglycans in cancer, Rap1 signaling pathway, Ras signaling pathway, Signaling pathways regulating pluripotency of stem cells, Transcriptional misregulation in cancer, mTOR signaling pathway |
5件: 78, 96, 168, 265, 299 |
70 |
Metformin |
Metformin |
D00944, D04966 |
2件: PRKAA1, PRKAA2 |
19件: AMPK signaling pathway, Adipocytokine signaling pathway, Apelin signaling pathway, Autophagy - animal, Circadian rhythm, Fluid shear stress and atherosclerosis, FoxO signaling pathway, Glucagon signaling pathway, Hypertrophic cardiomyopathy (HCM), Insulin resistance, Insulin signaling pathway, Longevity regulating pathway, Longevity regulating pathway - multiple species, Non-alcoholic fatty liver disease (NAFLD), Oxytocin signaling pathway, PI3K-Akt signaling pathway, Thermogenesis, Tight junction, mTOR signaling pathway |
16件: 6, 13, 46, 49, 67, 75, 77, 81, 86, 113, 158, 206, 225, 233, 265, 285 |
71 |
Metformin hydrochloride |
Metformin |
D00944, D04966 |
2件: PRKAA1, PRKAA2 |
19件: AMPK signaling pathway, Adipocytokine signaling pathway, Apelin signaling pathway, Autophagy - animal, Circadian rhythm, Fluid shear stress and atherosclerosis, FoxO signaling pathway, Glucagon signaling pathway, Hypertrophic cardiomyopathy (HCM), Insulin resistance, Insulin signaling pathway, Longevity regulating pathway, Longevity regulating pathway - multiple species, Non-alcoholic fatty liver disease (NAFLD), Oxytocin signaling pathway, PI3K-Akt signaling pathway, Thermogenesis, Tight junction, mTOR signaling pathway |
3件: 81, 158, 265 |
72 |
Metreleptin |
Metreleptin |
D05014 |
1件: LEPR |
6件: AMPK signaling pathway, Adipocytokine signaling pathway, Cytokine-cytokine receptor interaction, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, Non-alcoholic fatty liver disease (NAFLD) |
1件: 265 |
73 |
Metrelpetin |
- |
- |
- |
- |
1件: 265 |
74 |
Myalept |
Metreleptin |
D05014 |
1件: LEPR |
6件: AMPK signaling pathway, Adipocytokine signaling pathway, Cytokine-cytokine receptor interaction, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, Non-alcoholic fatty liver disease (NAFLD) |
1件: 265 |
75 |
Nelfinavir |
Nelfinavir |
D00899, D08259 |
- |
- |
3件: 49, 265, 331 |
76 |
Nelfinavir mesylate |
Nelfinavir |
D00899, D08259 |
- |
- |
1件: 265 |
77 |
Nevirapine |
Nevirapine |
D00435 |
- |
- |
1件: 265 |
78 |
Niacin |
Niacin |
D00049 |
- |
- |
3件: 6, 78, 265 |
79 |
Non-nucleoside reverse transcriptase inhibitors |
- |
- |
- |
- |
1件: 265 |
80 |
Norvir |
Ritonavir |
D00427 |
- |
- |
2件: 265, 299 |
81 |
Nucleomaxx |
- |
- |
- |
- |
1件: 265 |
82 |
Nucleoside analogue sparing haart regimen |
- |
- |
- |
- |
1件: 265 |
83 |
Nucleoside reverse transcriptase inhibitors |
- |
- |
- |
- |
1件: 265 |
84 |
Obeticholic acid |
Obeticholic acid |
D09360 |
1件: NR1H4 |
1件: Bile secretion |
3件: 93, 265, 296 |
85 |
Perform blood cells and fibroblasts biochemical and immuno-labeled investigations |
- |
- |
- |
- |
1件: 265 |
86 |
Pioglitazone |
Pioglitazone |
D00945, D08378 |
1件: PPARG |
9件: AMPK signaling pathway, Huntington disease, Longevity regulating pathway, Osteoclast differentiation, PPAR signaling pathway, Pathways in cancer, Thermogenesis, Thyroid cancer, Transcriptional misregulation in cancer |
17件: 2, 6, 13, 15, 20, 46, 49, 65, 67, 78, 81, 86, 96, 229, 265, 298, 299 |
87 |
Pioglitazone or metformin |
Pioglitazone |
D00945, D08378 |
1件: PPARG |
9件: AMPK signaling pathway, Huntington disease, Longevity regulating pathway, Osteoclast differentiation, PPAR signaling pathway, Pathways in cancer, Thermogenesis, Thyroid cancer, Transcriptional misregulation in cancer |
1件: 265 |
88 |
Pneumococcal polysaccharide vaccine 23 valent |
- |
- |
- |
- |
1件: 265 |
89 |
Pravastatin |
Pravastatin |
D00893, D08410 |
1件: HMGCR |
4件: AMPK signaling pathway, Bile secretion, Metabolic pathways, Terpenoid backbone biosynthesis |
9件: 13, 46, 49, 67, 79, 96, 164, 265, 333 |
90 |
Pravastatin sodium |
Pravastatin |
D00893, D08410 |
1件: HMGCR |
4件: AMPK signaling pathway, Bile secretion, Metabolic pathways, Terpenoid backbone biosynthesis |
1件: 265 |
91 |
Protease inhibitor |
- |
- |
- |
- |
1件: 265 |
92 |
Protease inhibitors |
- |
- |
- |
- |
1件: 265 |
93 |
R-methuleptin |
Metreleptin |
D05014 |
1件: LEPR |
6件: AMPK signaling pathway, Adipocytokine signaling pathway, Cytokine-cytokine receptor interaction, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, Non-alcoholic fatty liver disease (NAFLD) |
1件: 265 |
94 |
Raltegravir |
Raltegravir |
D06676 |
- |
- |
4件: 13, 26, 93, 265 |
95 |
Recombinant human growth hormone |
Somatotropin |
D02691 |
1件: GHR |
5件: Cytokine-cytokine receptor interaction, Growth hormone synthesis, secretion and action, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway |
3件: 78, 193, 265 |
96 |
Recombinant human growth hormone + rosiglitazone |
Rosiglitazone |
D00596, D08491 |
1件: PPARG |
9件: AMPK signaling pathway, Huntington disease, Longevity regulating pathway, Osteoclast differentiation, PPAR signaling pathway, Pathways in cancer, Thermogenesis, Thyroid cancer, Transcriptional misregulation in cancer |
1件: 265 |
97 |
Reyataz |
Atazanavir |
D01276, D07471 |
- |
- |
1件: 265 |
98 |
Riboflavin |
Riboflavin |
D00050, D01622, D01913 |
- |
- |
8件: 13, 38, 46, 96, 97, 162, 168, 265 |
99 |
Ritonavir |
Ritonavir |
D00427 |
- |
- |
4件: 2, 86, 130, 265 |
100 |
Ritonavir (norvir) |
Ritonavir |
D00427 |
- |
- |
1件: 265 |
101 |
Rosiglitazone |
Rosiglitazone |
D00596, D08491 |
1件: PPARG |
9件: AMPK signaling pathway, Huntington disease, Longevity regulating pathway, Osteoclast differentiation, PPAR signaling pathway, Pathways in cancer, Thermogenesis, Thyroid cancer, Transcriptional misregulation in cancer |
5件: 46, 75, 97, 222, 265 |
102 |
Rosiglitazone maleate |
Rosiglitazone |
D00596, D08491 |
1件: PPARG |
9件: AMPK signaling pathway, Huntington disease, Longevity regulating pathway, Osteoclast differentiation, PPAR signaling pathway, Pathways in cancer, Thermogenesis, Thyroid cancer, Transcriptional misregulation in cancer |
3件: 46, 75, 265 |
103 |
Saquinavir |
Saquinavir |
D00429, D01160 |
- |
- |
2件: 86, 265 |
104 |
Serostim®[somatropin (rdna origin) for injection] |
Somatotropin |
D02691 |
1件: GHR |
5件: Cytokine-cytokine receptor interaction, Growth hormone synthesis, secretion and action, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway |
1件: 265 |
105 |
Setmelanotide |
Setmelanotide |
- |
- |
- |
2件: 202, 265 |
106 |
Simvastatin |
Simvastatin |
D00434 |
1件: HMGCR |
4件: AMPK signaling pathway, Bile secretion, Metabolic pathways, Terpenoid backbone biosynthesis |
19件: 6, 13, 15, 34, 46, 49, 51, 66, 79, 86, 89, 94, 158, 162, 195, 265, 298, 299, 310 |
107 |
Somatropin |
Somatotropin |
D02691 |
1件: GHR |
5件: Cytokine-cytokine receptor interaction, Growth hormone synthesis, secretion and action, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway |
15件: 2, 3, 19, 46, 74, 75, 78, 96, 113, 193, 195, 265, 274, 276, 299 |
108 |
St200 |
- |
- |
- |
- |
1件: 265 |
109 |
Standard continuous antiretroviral therapy |
- |
- |
- |
- |
1件: 265 |
110 |
Stavudine |
Stavudine |
D00445 |
- |
- |
1件: 265 |
111 |
Sulfate |
Sulfate ion |
- |
- |
- |
22件: 2, 6, 11, 13, 26, 34, 36, 46, 49, 60, 61, 64, 66, 79, 86, 96, 222, 226, 265, 296, 297, 299 |
112 |
Sustiva |
Efavirenz |
D00896 |
- |
- |
1件: 265 |
113 |
Tat4 gel concentration a |
- |
- |
- |
- |
1件: 265 |
114 |
Tat4 gel concentration b |
- |
- |
- |
- |
1件: 265 |
115 |
Tenofovir |
Tenofovir |
D06074 |
- |
- |
5件: 2, 25, 93, 265, 325 |
116 |
Tenofovir df |
Tenofovir |
D06074 |
- |
- |
1件: 265 |
117 |
Tenofovir disoproxil |
Tenofovir disoproxil |
D01982 |
- |
- |
2件: 93, 265 |
118 |
Tenofovir disoproxil fumarate |
Tenofovir disoproxil |
D01982 |
- |
- |
1件: 265 |
119 |
Tesamorelin |
Tesamorelin |
D06655, D09015 |
1件: GHRHR |
2件: Growth hormone synthesis, secretion and action, Neuroactive ligand-receptor interaction |
2件: 78, 265 |
120 |
Tesamorelin (egrifta) |
Tesamorelin |
D06655, D09015 |
1件: GHRHR |
2件: Growth hormone synthesis, secretion and action, Neuroactive ligand-receptor interaction |
1件: 265 |
121 |
Testosterone |
Testosterone |
D00075, D00957, D00958, D00959, D06085, D06087 |
1件: AR |
3件: Oocyte meiosis, Pathways in cancer, Prostate cancer |
7件: 1, 2, 3, 13, 78, 113, 265 |
122 |
Th9507 |
- |
- |
- |
- |
1件: 265 |
123 |
Thiamine |
Thiamine |
D08580 |
- |
- |
2件: 13, 265 |
124 |
Tipranavir |
Tipranavir |
D03843, D08605 |
- |
- |
1件: 265 |
125 |
Total dietary replacement |
- |
- |
- |
- |
1件: 265 |
126 |
Truvada |
Tenofovir disoproxil |
D01982 |
- |
- |
1件: 265 |
127 |
Use of lipid-lowering drugs. |
- |
- |
- |
- |
1件: 265 |
128 |
Viracept versus sustiva with stavudine and epivir |
Stavudine |
D00445 |
- |
- |
1件: 265 |
129 |
Viral load driven treatment interruption |
- |
- |
- |
- |
1件: 265 |
130 |
Volanesorsen |
Volanesorsen |
D11648 |
1件: APOC3 |
2件: Cholesterol metabolism, PPAR signaling pathway |
1件: 265 |
131 |
Volanesorsen sodium, apoc-iii antisense oligonucleotide |
Volanesorsen |
D11648 |
1件: APOC3 |
2件: Cholesterol metabolism, PPAR signaling pathway |
1件: 265 |
132 |
Zidovudine |
Zidovudine |
D00413 |
- |
- |
6件: 25, 26, 135, 265, 325, 331 |